C ASE R EPORT: Dramatic response to lamivudine therapy following corticosteroid priming in chronic hepatitis B
C ASE R EPORT: Dramatic response to lamivudine therapy following corticosteroid priming in chronic hepatitis B
复制标题
DOI：
10.1046/j.1440-1746.1999.01960.x
复制
发表时间：
1999-08
影响因子：
4.1
通讯作者：
Y. Liaw;R. Chien
中科院分区：
文献类型：
--
作者：
Y. Liaw;R. Chien
1例21岁男性慢性B型肝炎患者在短期口服泼尼松龙（30 mg/d，持续3周，15 mg/d，持续1周）停药后接受拉米夫定150 mg/d治疗。泼尼松龙预治疗期间血清B型肝炎病毒（HBV）-DNA升高，泼尼松龙停药后血清丙氨酸氨基转移酶（ALT）升高。开始拉米夫定治疗后2个月内，HBV‐DNA清除，B e抗原血清转换和ALT正常化。如果进一步的研究证实了皮质类固醇预充后对拉米夫定治疗的这种显著反应，那么在这种特殊情况下使用的方案可能成为慢性HBV感染的强有力的治疗工具。
A 21 year‐old male patient with chronic hepatitis B was treated with lamivudine 150 mg daily after withdrawal of a short course of oral prednisolone (30 mg daily for 3 weeks, 15 mg daily for 1 week). Serum hepatitis B virus (HBV)‐DNA increased during prednisolone pretherapy and serum alanine aminotransferase (ALT) was increasing after withdrawal of prednisolone. Clearance of HBV‐DNA with hepatitis B e antigen seroconversion and ALT normalization occurred within 2 months after starting lamivudine therapy. If this dramatic response to lamivudine therapy after corticosteroid priming is confirmed by further studies, the regimens used in this particular case might become a powerful therapeutic tool for chronic HBV infection.